The Canadian Society of Allergy and Clinical Immunology is a little more forthcoming in their recommendations. At least for the community setting.
From the abstract, " Adverse effects of an epinephrine dose of 0.15 mg given intramuscularly in infants or children weighing less than 15 kg are expected to be mild and transient at the plasma epinephrine concentrations achieved; therefore, these effects need to be measured against the consequences of not receiving epinephrine at all, which can include fatality."
CSACI position statement: epinephrine auto-injectors and children < 15 kg
Allergy, Asthma & Clinical Immunology 2015, 11:20
For more information, send mail to [log in to unmask] with the message: info PED-EM-L
The URL for the PED-EM-L Web Page is: